Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 149Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Non-Hodgkin 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 81Hodgkin Disease 81Small Cell Lung Carcinoma 79Leukemia, Myeloid, Acute 73Burkitt Lymphoma 69Lymphoma, Follicular 67Lymphoma, Mantle-Cell 65Lung Neoplasms 60Lymphoma, Large-Cell, Immunoblastic 54Leukemia, Lymphocytic, Chronic, B-Cell 47Recurrence 40Multiple Myeloma 39Lymphoma, B-Cell, Marginal Zone 36Neuroblastoma 33Congenital Abnormalities 29Carcinoma, Non-Small-Cell Lung 28Lymphoma, B-Cell 25Myelodysplastic Syndromes 24Lymphoma, Large-Cell, Anaplastic 23Lymphoma, Extranodal NK-T-Cell 23Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Brain Neoplasms 22Sarcoma 21Ovarian Neoplasms 21Lymphoma, T-Cell, Peripheral 20Central Nervous System Neoplasms 20

Interventions

pembrolizumab 2Vorinostat 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2Bortezomib 2prednylidene 1pirarubicin 1etoposide phosphate 1Salvia hispanica seed extract 1Methotrexate 1Ifosfamide 1Everolimus 1Etoposide 1Cholecalciferol 1Brentuximab Vedotin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Subcutaneous panniculitis-like T-cell lymphoma × Etoposide × Clear all
NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡